18.11.2014 Views

09/2009 - Državni zavod za intelektualno vlasništvo

09/2009 - Državni zavod za intelektualno vlasništvo

09/2009 - Državni zavod za intelektualno vlasništvo

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

3558 HR - Patenti - Hrvatski glasnik <strong>intelektualno</strong>g vlasništva 16, 20<strong>09</strong>, 9, 3373 – 3601<br />

Podnositelj europske MKP Broj objave europske Naziv izuma<br />

prijave patenta<br />

prijave patenta<br />

(71) (51) (97) (54)<br />

Novartis AG, CH A61K 31/165 (2006.01)<br />

A61K 31/445 (2006.01)<br />

EP 2<strong>09</strong>4259 *<br />

A61K 31/549 (2006.01)<br />

A61K 45/06 (2006.01)<br />

A61P 9/12 (2006.01)<br />

Novartis AG, CH C07D 471/04 (2006.01)<br />

A61K 31/522 (2006.01)<br />

A61P 29/00 (2006.01)<br />

Novartis AG, CH C07D 471/04 (2006.01)<br />

A61K 31/4745 (2006.01)<br />

A61P 35/00 (2006.01)<br />

EP 2<strong>09</strong>4697 *<br />

EP 2<strong>09</strong>4700 *<br />

Novartis AG, CH C07D 498/04 (2006.01)<br />

A61K 31/424 (2006.01)<br />

EP 2<strong>09</strong>4713 *<br />

A61P 35/00 (2006.01)<br />

Novartis AG, CH C07D 233/40 (2006.01)<br />

C07D 401/12 (2006.01)<br />

EP 2<strong>09</strong>7386 *<br />

C07D 403/06 (2006.01)<br />

C07D 403/12 (2006.01)<br />

C07D 403/14 (2006.01)<br />

C07D 405/12 (2006.01)<br />

A61K 31/4178 (2006.01)<br />

A61P 35/00 (2006.01)<br />

Novartis AG, CH A61K 31/4045 (2006.01)<br />

A61K 31/53 (2006.01)<br />

EP 2<strong>09</strong>9451 *<br />

A61K 45/06 (2006.01)<br />

A61P 35/02 (2006.01)<br />

NovaShunt AG, CH A61F 2/04 (2006.01)<br />

A61M 5/00 (2006.01)<br />

EP 2086466 *<br />

NPS PHARMACEUTICALS, INC., CA A61K 31/165 (2006.01)<br />

A61K 31/16 (2006.01)<br />

EP 2<strong>09</strong>9444 *<br />

A61P 25/22 (2006.01)<br />

Nuvo Research Inc., CA A61K 9/06 (2006.01)<br />

A61K 31/196 (2006.01)<br />

EP 2086504 *<br />

A61K 47/10 (2006.01)<br />

A61K 47/32 (2006.01)<br />

A61K 47/36 (2006.01)<br />

A61K 47/38 (2006.01)<br />

A61K 9/00 (2006.01)<br />

NXP B.V., NL H04N 7/52 (2006.01)<br />

EP 1964295 *<br />

NXP B.V., NL H04B 3/30 (2006.01)<br />

NXP B.V., NL H04L 25/03 (2006.01)<br />

NXP B.V., NL H01L 21/768 (2006.01)<br />

H01L 21/321 (2006.01)<br />

H01L 23/532 (2006.01)<br />

NXP B.V., NL H04R 29/00 (2006.01)<br />

G01R 23/173 (2006.01)<br />

G01R 23/20 (2006.01)<br />

NXP B.V., NL G06T 1/60 (2006.01)<br />

NXP B.V., NL H01L 23/485 (2006.01)<br />

NXP B.V., NL H03F 3/217 (2006.01)<br />

NXP B.V., NL B81C 1/00 (2006.01)<br />

NXP B.V., NL H03K 19/003 (2006.01)<br />

H03K 19/0185 (2006.01)<br />

NXP B.V., NL G06F 17/30 (2006.01)<br />

NXP B.V., NL G06F 17/30 (2006.01)<br />

NXP B.V., NL G06F 17/30 (2006.01)<br />

NXP B.V., NL G06F 17/50 (2006.01)<br />

NXP, B.V., US G06F 13/42 (2006.01)<br />

Officine Meccaniche Galli S.r.l., IT A62B 23/02 (2006.01)<br />

OMYA DEVELOPMENT AG, CH C<strong>09</strong>C 1/02 (2006.01)<br />

C<strong>09</strong>C 3/10 (2006.01)<br />

EP 2087607 *<br />

EP 2087676 *<br />

EP 2089900 *<br />

EP 2<strong>09</strong>0138 *<br />

EP 2<strong>09</strong>2482 *<br />

EP 2<strong>09</strong>2561 *<br />

EP 2<strong>09</strong>2638 *<br />

EP 2<strong>09</strong>4602 *<br />

EP 2<strong>09</strong>55<strong>09</strong> *<br />

EP 2<strong>09</strong>7838 *<br />

EP 2<strong>09</strong>7839 *<br />

EP 2<strong>09</strong>7840 *<br />

EP 2100240 *<br />

EP 2054810 *<br />

EP 2<strong>09</strong>9532 *<br />

EP 1990376<br />

RENIN INHIBITORS FOR THE PREVENTION AND<br />

TREATMENT OF HYPERTENSION IN OBESE<br />

PATIENTS<br />

5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-<br />

7-OL DERIVATIVES AS CXCR2 ANTAGONISTS<br />

SALTS AND CRYSTALL FORMS OF 2-METHYL-2-[4-<br />

(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-<br />

IMIDAZO[4,5-C]QUINOLIN-1-YL)-PHENYL]-<br />

PROPIONITRILE<br />

EPOTHILONE ANALOGUES MODIFIED AT<br />

POSITIONS C12-C13 AS ANTICANCER DRUGS<br />

SUBSTITUTED DIHYDROIMIDAZOLES AND THEIR<br />

USE IN THE TREATMENT OF TUMORS<br />

COMBINATION OF AN HDAC INHIBITOR AND AN<br />

ANTIMETABOLITE<br />

AN IMPLANTABLE FLUID MANAGEMENT DEVICE<br />

FOR THE REMOVAL OF EXCESS FLUID<br />

USE OF D-SERINE DERIVATIVES FOR THE<br />

TREATMENT OF ANXIETY DISORDERS<br />

DICLOFENAC GEL<br />

METHOD OF SYNCHRONIZING THE PLAYBACK OF<br />

AN AUDIO BROADCAST ON A PLURALITY OF<br />

NETWORK OUTPUT DEVICES<br />

SIGNAL TRANSMISSION SYSTEM<br />

METHOD AND ARRANGEMENT FOR GENERATING<br />

SOFT BIT INFORMATION IN A RECEIVER OF A<br />

MULTIPLE ANTENNA SYSTEM<br />

FABRICATION OF A DIFFUSION BARRIER CAP ON<br />

COPPER CONTAINING CONDUCTIVE ELEMENTS<br />

METHOD OF DETERMINING THE HARMONIC AND<br />

ANHARMONIC PORTIONS OF A RESPONSE SIGNAL<br />

OF A DEVICE<br />

ADDRESS CALCULATION UNIT<br />

BOND PAD STRUCTURE AND METHOD FOR<br />

PRODUCING SAME<br />

CLASS-D AMPLIFIER<br />

A SEALING STRUCTURE AND A METHOD OF<br />

MANUFACTURING THE SAME<br />

CIRCUIT ARRANGEMENT FOR CONTROLLING A<br />

HIGH SIDE CMOS TRANSISTOR IN A HIGH<br />

VOLTAGE DEEP SUB MICRON PROCESS<br />

A METHOD FOR STORING DATA IN A RFID<br />

TRANSPONDER<br />

A METHOD FOR STORING DATA AS WELL AS A<br />

TRANSPONDER, A READ/WRITE-DEVICE, A<br />

COMPUTER READABLE MEDIUM INCLUDING A<br />

PROGRAM ELEMENT AND SUCH A PROGRAM<br />

ELEMENT ADAPTED TO PERFORM THIS METHOD<br />

A METHOD FOR STORING DATA IN A RFID<br />

TRANSPONDER<br />

DEVELOPMENT OF ASSERTIONS FOR INTEGRATED<br />

CIRCUIT DESIGN SIMULATION<br />

MAC AND PHY INTERFACE ARRANGEMENT<br />

NBC FILTER<br />

Procedure for the grinding of mineral materials and<br />

binders in an aqueous medium implementing a reverse<br />

emulsion of an acrylamide polymer with an acrylic<br />

monomer<br />

ISSN 1331-2030

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!